Quantcast

Latest JC virus Stories

7d6c5e2a2a65ac0a0e019d7364038c9d1
2008-12-15 14:42:08

On Monday, Biogen Idec Inc said it notified regulators of a new case of a potentially deadly brain disease in a patient being treated with its Tysabri multiple sclerosis drug, the fourth such case reported globally this year. Biogen stated in a regulatory filing that the latest case of the brain infection, known as progressive multifocal leukoencephalopathy (PML), was seen in a European patient that had been taking Tysabri as a stand-alone treatment for 26 months. Company spokeswoman Shannon...

2008-10-31 00:00:20

Biogen Idec Inc. says a U.S. woman contracted a deadly brain infection while taking the drug Tysabri. The drug maker said the woman contracted progressive multifocal leukoencephalopathy, or PML, while taking the drug alone rather than in conjunction with other drugs, The Wall Street Journal reported Thursday. The U.S. Food and Drug Administration said in August that using Tysabri alone may confer a lower risk of PML than when the drug is used together with other immunomodulatory...

2008-10-02 18:00:06

Genentech, Inc. (NYSE:DNA) announced today that the company has issued a Dear Healthcare Provider letter to inform potential prescribers of a case of progressive multifocal leukoencephalopathy (PML) in a 70-year old patient who had received Raptiva(R) (efalizumab) for more than four years for treatment of chronic plaque psoriasis. The company will work with the U.S. Food and Drug Administration (FDA) to update the prescribing information for Raptiva and determine if further action is needed....

2008-09-07 03:00:07

By Valle, Luis Del White, Martyn K; Khalili, Kamel Abstract The human polyomavirus JC (JCV) is a small DNA tumor virus and the etiologic agent of the progressive multifocal leukoencephalopathy. In progressive multifocal leukoencephalopathy, active JCV replication causes the lytic destruction of oligodendrocytes. The normal immune system prevents JCV replication and suppresses the virus into a state of latency so that expression of viral proteins cannot be detected. In a cellular context...

2008-04-25 03:00:20

By Shishido-Hara, Yukiko Higuchi, Kayoko; Ohara, Sinji; Duyckaerts, Charles; Hauw, Jean-Jacques; Uchihara, Toshiki Abstract Progressive multifocal leukoencephalopathy is a fatal demyelinating disorder due to human polyomavirus JC infection in which there are viral inclusions in enlarged nuclei of infected oligodendrocytes. We report that the pathogenesis of this disease is associated with distinct subnuclear structures known as promyelocytic leukemia nuclear bodies (PML-NBs). Postmortem...

2007-06-19 06:00:12

By McCalmont, Vicki Bennett, Kristi Progressive multifocal leukoencephalopathy is a rare, highly fatal demyelinating brain infection caused by the JC virus. This infection is associated with immunosuppressive agents and is emerging in the transplant population. There has never been a documented case of progressive multifocal leukoencephalopathy in a transplant recipient receiving sirolimus. We present a study, in which the JC virus was found in a 68-year-old man who had received a...

2006-04-07 03:51:55

By Michael Smith DUBLIN (Reuters) - Elan Corp. Plc said on Friday the latest trials of its multiple sclerosis drug Tysabri showed significant positive results in patients, sending its shares higher. "The Tysabri study data show not only significant reductions in relapses and disability, but also suggest improved quality of life. This is very encouraging," the company said in a statement. Elan and drugmaker Biogen Idec faced a fresh delay in getting Tysabri back to the market last...

2006-03-29 20:41:12

CHICAGO (Reuters) - Biogen Idec and Elan Corp said on Wednesday they have restarted a safety trial of its multiple sclerosis drug Tysabri, which the drugmakers recalled from the market after reports of rare brain infection were linked to the drug. A U.S. Food and Drug Administration panel earlier this month recommended the drug be returned to the market, with mandatory controls for risks and new cases of the fatal side effect, linked to two deaths. The companies expect an action by...

2006-03-08 15:07:29

By Lisa Richwine GAITHERSBURG, Maryland (Reuters) - A panel of independent experts on Wednesday unanimously urged the U.S. return of Biogen Idec's multiple sclerosis drug Tysabri, a medicine abruptly pulled from the market last year after it was linked to a life-threatening side effect. If the Food and Drug Administration followed the recommendation, it would signal a reversal of fortune for Biogen and partner Elan Corp. of Ireland, and a victory for MS patients who have pleaded for...

2006-03-08 10:59:41

GAITHERSBURG, Maryland (Reuters) - Biogen Idec and Elan's multiple sclerosis drug Tysabri could be used as a first-choice treatment for some patients if it returns to the market, a U.S. advisory panel said on Wednesday. The committee voted 7-5 in favor of Tysabri as an initial treatment for some patients. The panel was due to vote later Wednesday on whether to recommend resumed sales for the drug, which was pulled from the market in February 2005 after three patients developed a...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related